Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 2,590,000 shares, a decline of 94.6% from the March 31st total of 47,720,000 shares. Based on an average trading volume of 665,300 shares, the days-to-cover ratio is currently 3.9 days. Currently, 13.0% of the shares of the company are short sold.

Insider Activity

In other Agenus news, insider Garo H. Armen bought 25,000 shares of the business's stock in a transaction dated Thursday, February 15th. The shares were acquired at an average cost of $13.00 per share, with a total value of $325,000.00. Following the acquisition, the insider now directly owns 31,298 shares of the company's stock, valued at approximately $406,874. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company's stock.

Institutional Trading of Agenus

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Agenus in the third quarter valued at approximately $36,000. PCG Wealth Advisors LLC boosted its stake in shares of Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company's stock valued at $39,000 after buying an additional 18,850 shares during the last quarter. RPO LLC purchased a new position in shares of Agenus during the 4th quarter valued at approximately $43,000. Lindbrook Capital LLC boosted its stake in shares of Agenus by 38.8% during the 3rd quarter. Lindbrook Capital LLC now owns 52,535 shares of the biotechnology company's stock valued at $59,000 after buying an additional 14,674 shares during the last quarter. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of Agenus during the 4th quarter valued at approximately $65,000. Institutional investors and hedge funds own 61.46% of the company's stock.

Agenus Price Performance

NASDAQ:AGEN traded up $0.88 on Thursday, reaching $8.30. The stock had a trading volume of 960,558 shares, compared to its average volume of 628,664. The company has a market cap of $173.89 million, a price-to-earnings ratio of -0.56 and a beta of 1.26. The firm's fifty day moving average is $11.06 and its two-hundred day moving average is $13.83. Agenus has a 12-month low of $4.78 and a 12-month high of $42.60.

Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($2.20). The business had revenue of $83.80 million for the quarter, compared to the consensus estimate of $54.21 million. As a group, research analysts forecast that Agenus will post -8.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AGEN has been the topic of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $160.00 price objective on shares of Agenus in a research note on Thursday, March 14th. B. Riley decreased their price objective on shares of Agenus from $120.00 to $100.00 and set a "buy" rating on the stock in a research report on Monday, March 18th. Finally, StockNews.com initiated coverage on shares of Agenus in a research report on Wednesday, April 17th. They issued a "hold" rating on the stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.